https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53913 Wed 28 Feb 2024 15:58:52 AEDT ]]> Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47009 Tue 13 Dec 2022 11:34:29 AEDT ]]> Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44354 Tue 11 Oct 2022 19:42:45 AEDT ]]> PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55040 Thu 04 Apr 2024 13:51:52 AEDT ]]> A road map for the treatment of pediatric diffuse midline glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53880 Fri 19 Jan 2024 12:44:57 AEDT ]]> ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53140 Fri 17 Nov 2023 11:42:18 AEDT ]]>